Abstract
Neovascular glaucoma (NVG) is a refractory ophthalmopathy secondary to multiple ophthalmic and generic vascular diseases, and frequently causes the patients vision loss and impacts their quality of life. The past treatments had very high failure rate: medications did not show good effects, and surgeries led to complications such as intraoperative bleeding, postoperative serious local inflammatory reaction and filtering bleb scar etc. Its pathogenesis is that vascular endothelial growth factor (VEGF) gene overexpression caused by anoxic ischemic retinopathy increases the amount of VEGF in aqueous humor, and then stimulates neovascularization at iris and chamber angel. Anti-VEGF medications being generally applied in ophthalmology in recent years lead the treatment of NVG to a new era. This article briefly summarized the application of anti-VEGF medication in the treatment of NVG. Key words: Glaucoma, neovascular; Anti-VEGF; Treatment
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Chinese Journal of Ocular Trauma and Occupational Eye Disease
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
